Suppr超能文献

自体血清滴眼液治疗重度干眼综合征的疗效:一项随机双盲交叉研究。

The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study.

作者信息

Celebi Ali Riza Cenk, Ulusoy Cemalettin, Mirza G Ertugrul

机构信息

Department of Ophthalmology, Republic of Turkey, Ministry of Health, Nigde State Hospital, Feridun Zeren Street, 51000, Nigde, Turkey,

出版信息

Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):619-26. doi: 10.1007/s00417-014-2599-1. Epub 2014 Feb 25.

Abstract

BACKGROUND

To evaluate the efficacy of autologous serum (AS) eye drops for the symptomatic relief of severe dry eye syndrome (DES), as compared to conventional preservative-free artificial tears (PFAT).

METHODS

This prospective double-blind randomized crossover study used the Ocular Surface Disease Index (OSDI), tear film break-up time (TBUT), Schirmer's Test, and OXFORD Scale at baseline and after each of two 1-month treatment periods to measure the effect of 20 % diluted AS eye drops vs. PFAT in 20 consecutive severe DES patients that were refractory to conventional treatment.

RESULTS

The study included 20 (18 female and two male) severe DES patients (40 eyes). Significantly higher TBUT (P < 0.001, Wilcoxon signed-rank test) and a greater decrease in OSDI score (55.18 % decrease in the AS treatment group vs. 19.50 % decrease in the PFAT treatment group) (P < 0.001, Student's paired samples t-test) were observed in the AS treatment group after 1 month of treatment. There wasn't a significant difference in Schirmer's test and OXFORD conjunctival and corneal vital dying grading scores between the two treatment groups after 1 month of treatment (P > 0.05 [Mann-Whitney U test]).

CONCLUSIONS

AS eye drops were more effective than conventional eye drops for improving tear film stability and subjective comfort in patients with severe DES.

摘要

背景

评估自体血清(AS)滴眼液与传统无防腐剂人工泪液(PFAT)相比,对重症干眼综合征(DES)症状缓解的疗效。

方法

这项前瞻性双盲随机交叉研究,在基线以及两个1个月治疗期的每一期结束后,使用眼表疾病指数(OSDI)、泪膜破裂时间(TBUT)、Schirmer试验和牛津量表,来测量20%稀释的AS滴眼液与PFAT对20例连续的常规治疗无效的重症DES患者的治疗效果。

结果

该研究纳入了20例(18例女性和2例男性)重症DES患者(40只眼)。治疗1个月后,AS治疗组观察到TBUT显著升高(P < 0.001,Wilcoxon符号秩检验),OSDI得分显著降低(AS治疗组降低55.18%,PFAT治疗组降低19.50%)(P < 0.001,Student配对样本t检验)。治疗1个月后,两组之间Schirmer试验以及牛津结膜和角膜活体染色分级得分无显著差异(P > 0.05[Mann-Whitney U检验])。

结论

对于改善重症DES患者的泪膜稳定性和主观舒适度,AS滴眼液比传统滴眼液更有效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验